CGRP Forum
Send to a colleague
Register  Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

Latest News

In case you missed it… Recent News from the CGRP Forum

It was a memorable Summer for clinicians with an interest in migraine and for their patients, with anti-CGRP therapies regularly making headlines. At the Forum, we reported a wealth of important new data and launched a valuable resource for clinicians showing worldwide anti-CGRP therapy availability and indications.

  • In June, Emgality (galcanezumab) became the first CGRP antibody to be approved for episodic cluster headache prevention in the USA, and the following month rimegepant moved into trigeminal neuralgia trials.
  • With migraine the focus of World Brain Day for the first time, CGRP Forum Editors, David Dodick and Peter Goadsby, were among leading migraine specialists urging policymakers to prioritise migraine and achieve benefits for patients and society.
  • Reporting data from three major congresses in Europe and the USA, the Forum brought together latest long term and real world data for anti—CGRP therapies — demonstrating their sustained efficacy and how they are taking their place in clinical practice.
  • For clinicians considering whether to prescribe anti-CGRP therapies for paediatric patients, the Forum‘s latest Hot Topic presented an accessible guide to the evidence.
    • And finally… new this week on the Forum, CGRP in the Journals is a useful service for members. It summarises some of the most important CGRP publications of the last 12 months and will be regularly updated.

    Read CGRP in the Journals here »

Catch up at:

Is anti-CGRP therapy approved for your patients?

Emgality (galcanezumab) gains US approval for episodic cluster headache treatment

Rimegepant moves into trigeminal neuralgia trials

Wake up to World Brain Day — 22 July 2019

Erenumab real-world experience supports clinical trial data

Fremanezumab demonstrates 10-year cost effectiveness

What do clinicians need to know when prescribing CGRP inhibitors to children and adolescents?

For all the other recent migraine news featured on the CGRP Forum click here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Logos
© Copyright CGRP Forum 2019. Please click here to unsubscribe from future mailings.